Board of Directors

Ulf Wiinberg

Chairman of the board since 2016

Ulf Wiinberg is an experienced healthcare industry professional who has served on the boards of several healthcare industry associations. At Wyeth, he has been both President of the global consumer health care business and President for the European pharma business, and he has also held the position as CEO of H Lundbeck A/S, a pharmaceutical company specialized in psychiatric and neurological disorders, for several years. Ulf is a non-executive member of the board of Alfa Laval AB, Agenus Inc and at the Belgian pharmaceutical company UCB. He is also chairman of the board of Sigrid Therapeutics AB as well as CEO and chairman of the board of Ulf Wiinberg Consulting&Invest AB. Born in 1958.

Ulf is chairman of Hansa Medical’s Remuneration Committee, and member of the Audit Committee.
Independent of Hansa Medical and its senior management. Independent of major shareholders of Hansa Medical.

Shareholding: 85,000

Birgit Stattin Norinder

Member of the board since 2012

Birgit has extensive experience from international pharmaceutical and biotechnology companies in Sweden, the USA and the United Kingdom. She has managed several research and development departments, resulting in a number of novel and approved pharmaceuticals. Amongst many things she has served as CEO and Chairman at Prolifix Ltd., Senior VP Worldwide Product Development, Pharmacia & Upjohn and Dir. Int. Reg. Affairs Division, Glaxo Group Research Ltd. Birgit has also held several board and chairman positions of European biotechnology companies. She is member of the board of AddLife AB and Jettesta AB. Chairman of the Board of Hansa Medical 2014-2016. Birgit holds an M.Sc. in Pharmacy from Uppsala University. Born in 1948.

Birgit is chairman of Hansa Medical’s Scientific Committee, and member of the Audit Committee and the Remuneration Committee. Independent of Hansa Medical and its senior management. Independent of major shareholders of Hansa Medical.

Shareholding: 39,205

Mats Blom

Member of the board since 2019

Mats Blom has extensive managerial experience and is Chief Financial Officer (CFO) of Modus Therapeutics AB. Prior to joining Modus, he served as CFO of Zealand Pharma A/B, a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines, and Swedish Orphan International, an orphan drug company acquired by BioVitrum in 2009. In addition, Mats has held CFO positions at Active Biotech AB and Anoto Group AB. He has also served as a management consultant at Gemini Consulting and Ernst & Young. Mats Blom holds a BA in Business Administration and Economics from the University of Lund and an MBA from IESE University of Navarra, Barcelona.

 

Shareholding: 

Eva Nilsagård

Member of the board since 2019

Eva Nilsagård is currently interim CFO at OptiGroup AB and founder and CEO of Nilsagård Consulting AB. She has served as CFO of Vitrolife and Plastal, Senior Vice President Strategy & Business Development at Volvo Group and held senior positions in finance and business development at Volvo, AstraZeneca and SKF. Eva is a board member and chairman of the audit committee of Addlife, Bufab, Irras and Xbrane Biopharma, and board member of SEK (Swedish Export Credit Company). Eva has more than ten years of experience as a mentor for young female managers with high potential. Eva Nilsagård holds an Executive MBA in Economics and a Bsc in accounting and finance from School of Business, Economics and Law in Gothenburg.

Shareholding: -

Anders Gersel Pedersen

Member of the board since 2018

Anders has a long experience from the international pharmaceutical industry. Following his degree in medicine and research fellow positions at Copenhagen hospitals, he worked for Eli Lilly for 11 years. In January 2000 he joined H. Lundbeck A/S in Denmark and is currently Executive Vice President of the Research & Development organization, hence responsible for the discovery and development of the product pipeline from pre-clinical activities to post-launch marketing studies. He is a member of Danish Society of Internal Medicine and serves on the supervisory boards of ALK-Abelló A/S, Bavarian Nordic A/S, and Genmab A/S. Anders received his medical degree and a doctoral degree in neuro-oncology from the University of Copenhagen and a B.Sc. in Business Administration from Copenhagen Business School. Born in 1951.

Independent of Hansa Medical and its senior management. Independent of major shareholders of Hansa Medical.

Shareholding: -

Andreas Eggert

Member of the board since 2018

Andreas has more than 20 years of cross-functional leadership experience including commercial operations, launch and portfolio management, brand strategy, market access, and strategic consulting. He served as Senior Group Vice President, Global Product Strategy & Portfolio Development, and Member of the Corporate Management Committee at H. Lundbeck A/S in Denmark, where he was responsible for multiple new product launches and the commercial leadership for shaping the product portfolio and development pipeline. Previously, Andreas served as Vice President & Global Business Manager at Wyeth/Pfizer in the US. He held several senior commercial positions for Wyeth in the US, Japan and in Germany. Andreas also was a Management Consultant at A.T. Kearney. He holds an MBA from Azusa Pacific University. Born in 1967.

Independent of Hansa Medical and its senior management. Independent of major shareholders of Hansa Medical.

Shareholding: 2,500